RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020
27 févr. 2020 07h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on...
Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020
26 févr. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Sterility Testing Market To Reach USD 1.18 Billion By 2026 | Reports and Data
25 févr. 2020 14h00 HE
|
Reports and Data
New York, Feb. 25, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Sterility Testing market was valued at USD 466.0 million in 2018 and is expected to...
Bioburden Testing Market To Reach USD 1.28 Billion By 2026 | Reports and Data
25 févr. 2020 11h00 HE
|
Reports and Data
New York, Feb. 25, 2020 (GLOBE NEWSWIRE) -- The global bioburden testing market is projected to grow at a CAGR of 12.7%, in terms of value, from 2016 to reach USD 1.28 billion by 2026. Bioburden...
RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca
25 févr. 2020 02h00 HE
|
RedHill Biopharma Ltd.
RedHill to promote Movantik® in the U.S. upon closing Movantik® generated U.S. net sales of $96 million in 2019Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the...
RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
25 févr. 2020 02h00 HE
|
RedHill Biopharma Ltd.
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia® this quarter and the ongoing promotion of Aemcolo® RedHill will receive...
Trevi Therapeutics to Present at SVB Leerink Healthcare Conference
20 févr. 2020 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors
18 févr. 2020 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
CureVac berichtet positive Ergebnisse aus niedrig dosierter 1 µg Phase-1-Studie mit Tollwut-Impfstoff
07 janv. 2020 07h00 HE
|
CureVac AG
Impfung induziert selbst bei niedriger Dosierung bei sämtlichen Probanden eine Immunantwort und ist gut verträglich Klinische Ergebnisse unterstreichen Potenzial von CureVacs...
CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study
07 janv. 2020 07h00 HE
|
CureVac AG
Low dose vaccination induced immune response in all subjects and was well tolerated Clinical results underline potency of CureVac’s technology platform Detailed results to be presented at an upcoming...